Sertraline for Major Depressive Disorder

Inspect the conclusion, its exact scope, the statements used to support it, and when each source was checked. This page does not add clinical advice or extend the published research beyond its stated scope.

Published assessment

Only this Treatment × Need pair is assessed here.

1 distinct published sources

Research suggests benefit in this exact scope

Published Sep 20, 2026 · revision 1

Reasoning and support

Open any source row to inspect scope and supporting text.

conclusion

The current ZOLOFT label reports randomized, double-blind, placebo-controlled studies supporting its MDD evidence scope. This bounded assessment does not compare every option or determine personal suitability.

DailyMed sertraline (Zoloft) label · checked Sep 20, 2026

Relationship: supports bounded conclusion

Scope: country:US

Pointer: /sections/1

Supporting passage: The efficacy of ZOLOFT as a treatment for MDD was established in two randomized, double-blind, placebo-controlled studies and one double-blind, randomized-withdrawal study following an open label study in adult (ages 18 to 65) outpatients who met the Diagnostic and Statistical Manual of Mental Disorders (DSM-III) criteria for MDD (studies MDD-1 and MDD-2).

Open source

Relationship source

Why this Treatment appears in the Need landscape, separate from the research conclusion.

DailyMed sertraline (Zoloft) label · checked Sep 20, 2026

Relationship: label-reported clinical studies for the Need

Scope: country:US

Pointer: /sections/1

Supporting passage: The efficacy of ZOLOFT as a treatment for MDD was established in two randomized, double-blind, placebo-controlled studies and one double-blind, randomized-withdrawal study following an open label study in adult (ages 18 to 65) outpatients who met the Diagnostic and Statistical Manual of Mental Disorders (DSM-III) criteria for MDD (studies MDD-1 and MDD-2).

Open source

See something wrong? Tell us. Your note is private. We check sources before we change this page.